SIM0235 represents a humanized immunoglobulin G1 (IgG1) monoclonal antibody with a specific affinity toward and inhibition of TNFR2. This antibody showcases the ability to effectively eliminate TNFR2-expressing immunosuppressive cells, encompassing regulatory T cells (Tregs) and bone marrow-derived suppressor cells. Its mechanism involves the utilization of antibody-dependent cellular cytotoxicity (ADCC), antibody-dependent cellular phagocytosis (ADCP), and other Fc-receptor functions.
Moreover, this remarkable molecule demonstrates the capability to impede TNFR2 activation by endogenous tumor necrosis factor (TNF), thereby exerting influence over the immunosuppressive function and proliferation typically mediated by TNFR2. Consequently, this augmentation serves to bolster the body's immune response against tumors. Notably, SIM0235 exhibits an additional proficiency in binding to TNFR2 present on the surface of tumor cells, subsequently effecting their direct elimination.